Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $376.82
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 8, 26 |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 13, 26 | Wang Xiaodong | director, other: Chair, Scientific Advisory Brd | M-Exempt | 403,351 @ $2.84 | $1.15M |
| RBC Capital |
| maintain |
| Outperform |
| Outperform |
| Oct 7, 26 | Truist Securities | maintain | Buy | Buy |
| Oct 1, 26 | JP Morgan | maintain | Overweight | Overweight |
| Sep 10, 26 | Barclays | maintain | Overweight | Overweight |
| Aug 6, 26 | Barclays | maintain | Overweight | Overweight |
| Aug 6, 26 | Citizens | maintain | Market Outperform | Market Outperform |
| Aug 6, 26 | Truist Securities | maintain | Buy | Buy |
| Aug 6, 26 | TD Cowen | maintain | Buy | Buy |
| Aug 6, 26 | RBC Capital | maintain | Outperform | Outperform |
| Oct 13, 26 |
| Wang Xiaodong |
| director, other: Chair, Scientific Advisory Brd |
| M-Exempt |
| 31,027 @ $36.90 |
| $1.14M |
| Oct 13, 26 | Wang Xiaodong | director, other: Chair, Scientific Advisory Brd | S-Sale | 7,167 @ $349.56 | $2.51M |
| Oct 13, 26 | Wang Xiaodong | director, other: Chair, Scientific Advisory Brd | S-Sale | 10,361 @ $350.47 | $3.63M |
| Oct 13, 26 | Wang Xiaodong | director, other: Chair, Scientific Advisory Brd | S-Sale | 5,681 @ $351.40 | $2.00M |
| Oct 13, 26 | Wang Xiaodong | director, other: Chair, Scientific Advisory Brd | S-Sale | 6,558 @ $352.57 | $2.31M |
| Oct 13, 26 | Wang Xiaodong | director, other: Chair, Scientific Advisory Brd | S-Sale | 1,260 @ $353.24 | $445.1K |
| Sep 30, 26 | Lee Chan Henry | officer: SVP, General Counsel | S-Sale | 1,115 @ $375.00 | $418.1K |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Stock news · updated daily
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GE.
BeOne Medicines AG is a fast-growing oncology company and a Wall Street favorite. Tevimbra, its PD-1 inhibitor, helped drive growth, with Q2 revenue rising 10.8% QoQ and 18.1% YoY to $228.5 million. BeOne's rich pipeline includes BGB-B2033, BG-C477, and BGB-58067, with clinical data scheduled for presentation at the 2026 ESMO Congress, taking place October 23-27.
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com.To ensure a.
Oncolytics Biotech Inc. (TSE: ONC - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of C$14.90 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares traded. Oncolytics Biotech Stock Down 1.3% The company
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-bre.
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ: ONC - Get Free Report) insider Xiaodong Wang sold 31,027 shares of BeOne Medicines stock in a transaction on Tuesday, October 13th. The shares were sold at an average price of $350.99, for a total value of $10,890,166.73. Following the sale, the insider directly owned 31,027 shares of the
BeOne Medicines Ltd. - Sponsored ADR (ONC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
KMX, ACIC, ONC, ODD and WES have been added to the Zacks Rank #1 (Strong Buy) List on October 15, 2026.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | 1.63 | 2.05 | Beat 25.8% | $1.71B |
| May 6, 2026 | 0.73 | 1.96 | Beat 168.5% | $1.51B |
| Feb 26, 2026 | 1.60 | 0.58 | Miss -63.7% | $1.50B |
| Nov 6, 2025 | 0.72 | 1.09 | Beat 51.4% | $1.41B |
| Aug 6, 2025 | 0.48 | 0.84 | Beat 75.0% | $1.32B |
| May 7, 2025 | -0.71 | 1.22 | Beat 271.8% | $1.12B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 15, 2026 | 2026-10-15 17:08:40 | View |
| 4 | Oct 2, 2026 | 2026-10-02 16:53:14 | View |
| 4 | Sep 30, 2026 | 2026-09-30 17:11:24 | View |
| SC 13D/A | Sep 16, 2026 | 2026-09-16 16:24:41 | View |
| 4 | Sep 16, 2026 | 2026-09-16 16:18:45 | View |
| 4 | Sep 10, 2026 | 2026-09-10 16:49:55 | View |
| 144 | Sep 8, 2026 | 2026-09-08 16:26:01 | View |
| 4 | Sep 3, 2026 | 2026-09-03 17:17:16 | View |
| 144 | Sep 1, 2026 | 2026-09-01 16:14:52 | View |
| 4 | Aug 27, 2026 | 2026-08-27 17:12:32 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | ONC | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 27.8x | -14.3x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 51.8x | EPS est. 7.28 | Elevated |
| Price / Book | 11.7x | 5.6x | Elevated |
| Price / Sales | 7.1x | 11.2x | Discount |
| EV / EBITDA | 35.3x | -9.5x | Discount |
| Return on equity | 14.3% | — | Healthy |
| Gross margin | 87.8% | 84.4% | In line |
| Debt / Equity | 0.22 | 0.26 | Conservative |
| Piotroski / Altman Z | 6/9 | Z 6.59 | Safe zone |
Discounted cash flow model
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 58.16 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 85.76 | Oscillator | Sell |
| Williams %R (14) | -24.90 | Oscillator | Neutral |
| MACD (12, 26, 9) | 6.02 (Hist 2.28) | Oscillator | Strong Buy |
| Average Directional Index (14) | 13.36 (+DI 27.2 / -DI 22.8) | Trend | Neutral |
| EMA 20 | 367.54 | MA | Buy |
| SMA 20 | 365.11 | MA | Strong Buy |
| EMA 50 | 357.50 | MA | Strong Buy |
| SMA 50 | 362.59 | MA | Strong Buy |
| SMA 200 | 324.09 | MA | Strong Buy |